At-Home Versus In-Clinic INR Monitoring: A Cost–Utility Analysis from The Home INR Study (THINRS)

Journal of General Internal Medicine

Volumn 31, Issue 9, 2016, Pages 1061-1067

  Phibbs, Ciaran S ^a,b,c   Love, Sean R ^d,e   Jacobson, Alan K ^c,f   Edson, Robert ^a   Su, Pon ^a   Uyeda, Lauren ^a   Matchar, David B ^d,g,h   writing for the THINRS Executive Committee and Site Investigators, ⁱ  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e BROWN UNIVERSITY   (United States)

^f LOMA LINDA UNIVERSITY   (United States)

^g DURHAM VA MEDICAL CENTER   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Durham VA Medical Center ^*

Author keywords

anticoagulants; atrial fibrillation; cost effectiveness; heart valve; randomized trials

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CLOPIDOGREL; TICLOPIDINE; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASSESSMENT OF HUMANS; ATRIAL FIBRILLATION; CHADS2 SCORE; COMPETENCE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH UTILITIES INDEX; HEART ARRHYTHMIA; HIGH QUALITY ANTICOAGULATION MANAGEMENT; HOME MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; MULTICENTER STUDY; OPEN STUDY; PATIENT SELF TESTING; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; HOME CARE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PROCEDURES; PUBLIC HOSPITAL; SELF CARE; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HOME CARE SERVICES; HOSPITALS, VETERANS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SELF CARE; WARFARIN; YOUNG ADULT;

EID: 84970996558     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-016-3700-8     Document Type: Article

References (29)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–198S.
2. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796–807.
3. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42–51.
4. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ. Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). J Thromb Thrombolysis. 2000;9(Suppl 1):S7–11.
5. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–1647.
6. Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010:CD003839.
7. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608–1620.
8. Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007;118:54–61.
9. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379:322–334.
10. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9:283–292.
11. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–184S.
12. Horseman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): Concepts, Measurement Properties and Applications. Health and Quality of Life Outcomes (electronic journal). 2003;1.
13. Matchar DB, Love SR, Jacobson AK, et al. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015;40:17–25.
14. Matchar DB, Jacobson AK, Edson RG, et al. The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481-The Home INR Study (THINRS). J Thromb Thrombolysis. 2005;19:163–172.
15. Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis. 2010;30:263–275.
16. CPI Tables. www.bls.gov/cpi/#tables. Accessed 3 February 2016.
17. Amazon.com: INR meter. http://www.amazon.com/s/ref=nb_sb_noss_2?url=search-alias%3Daps&field-keywords=INR+meter. Accessed 3 February 2016.
18. Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004;2:22.
19. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2002.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1253–1258.
21. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1339–1341.
22. Glick H. Web Resources for Economic Evaluation in Clinical Trials. 2012; http://www.uphs.upenn.edu/dgimhsr/eeinct.htm. Accessed 3 February 2016.
23. Glick H, Doshi J, Sonnad S, Polsky D. Economic evaluation in clinical trials. Oxford, UK: Oxford University Press; 2007.
24. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344–349.
25. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999;15:141–155.
26. Table: Threshold values for intervention cost-effectiveness by Region. http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed 3 February 2016.
27. Russell LB. Completing costs: patients' time. Med Care. 2009;47:S89–93.
28. Holder KA. The Educational Attainment of Veterans: 2007. 2009; https://www.census.gov/hhes/veterans/files/veteranseducation.pdf. Accessed 3 February 2016.
29. Turakhia MP, Hoang DD, Xu X, et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. Am Heart J. 2013;165:93–101.